Clinical Updates on the Treatment of Advanced Cholangiocarcinoma
EP. 1: Cholangiocarcinoma Described
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Dr Sameek Roychowdhury, of the James Cancer Hospital Solove Research Institute, describes what cholangiocarcinoma is, specifically highlighting how the disease often presents in patients.
EP. 2: Heterogeneous Nature of Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center GI oncologists explain the complicated nature of cholangiocarcinoma as it relates to the disease’s underlying pathogenesis.
EP. 3: Rising Incidence of Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Factors that may contribute to the rise in the number of cholangiocarcinoma cases being reported, as suggested by GI oncologists.
EP. 4: Cholangiocarcinoma: Appropriate Diagnostic Work-Up
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Types of assessments that are used to help appropriately work up a patient suspected of having a bile duct cancer.
EP. 5: Cholangiocarcinoma: Importance of Adequate Tissue Collection
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Best practices for working with other colleagues to ensure adequate tissue collection occurs when conducting a biopsy on a patient suspected of having cholangiocarcinoma, as well as considerations for next-generation sequencing.
EP. 6: Advanced Cholangiocarcinoma: Current Patient Prognosis
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center GI oncologists react to a prognosis for patients with newly diagnosed advanced cholangiocarcinoma and discuss how they counsel patients on goals of care and treatment expectations.
EP. 7: Advanced Cholangiocarcinoma: Criteria for Resection
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Panelists discuss types of scans and other testing results that can be used to help identify patients with an advanced bile duct cancer who are eligible for surgical resection.
EP. 8: Liver Transplantation for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Scenarios for which liver transplantation may be appropriate in advanced cholangiocarcinoma.
EP. 9: Adjuvant Therapy for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Current treatment approaches for advanced cholangiocarcinoma, despite current gaps that can be considered in the adjuvant setting, as highlighted by GI oncologists.
EP. 10: Optimizing Adjuvant Therapy for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Insight regarding best timing to initiate an appropriate adjuvant therapy in patients with advanced cholangiocarcinoma, and the role of ctDNA analysis in the postsurgical setting.
EP. 11: Neoadjuvant Therapy for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center An overview of potential options, as well as trials, further exploring neoadjuvant approaches for the management of patients with advanced cholangiocarcinoma.
EP. 12: Treating Unresectable, Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Treatment recommendations, including supportive care options and the role of liver-directed therapy for patients with an unresectable, advanced bile duct cancer.
EP. 13: Advanced Cholangiocarcinoma: Transition to Precision Medicine
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center A panel of GI oncologists comment on the transition to targeted therapy and immunotherapy as treatments for advanced cholangiocarcinoma, as well as highlight predictive and prognostic markers that can help guide treatment decisions with novel therapies.
EP. 14: Advanced Cholangiocarcinoma: Molecular Testing
ByJohn L. Marshall, MD, Georgetown University,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Experts who treat patients with GI cancers, such as cholangiocarcinoma, emphasize the need for more standardized approaches to molecular testing.
EP. 15: Promoting the Importance of Molecular Testing in CCA
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center The value of early molecular testing in cholangiocarcinoma and importance of promoting its role to both patients and GI oncologists.
EP. 16: FGFR Inhibitors for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.
EP. 17: FGFR Inhibitors for Advanced Cholangiocarcinoma: Adverse Events
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Recommendations for appropriately managing patients who experience adverse events associated with FGFR treatment for advanced cholangiocarcinoma.
EP. 18: Implications for Using FGFR Inhibitors in Advanced CCA
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, explains what GI oncologists can expect from FGFR treatment for advanced cholangiocarcinoma in terms of treatment responses.
EP. 19: IDH Targeting in Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, University of California-San Francisco,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center Considerations for treating appropriate patients with advanced cholangiocarcinoma with an IDH inhibitor.
EP. 20: Cholangiocarcinoma: Potential Therapies Under Investigation
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, University of California-San Francisco,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center An overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.
EP. 21: Immunotherapy for Advanced Cholangiocarcinoma
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center The role of MSI testing and potential use of immunotherapy to treat patients with advanced cholangiocarcinoma.
EP. 22: Perspectives on Treating CCA Moving Forward
ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.
